Table 3 . Patient characteristics .
| Paper | patients | ||
| Klotz |
Degarelix 240/160mg (n=202) |
Degarelix 240/80mg (n=207) |
Leuprorelin 7.5mg (n=201) |
| Mean age (range), year | 72 (50-88) | 72 (51-89) | 74 (52-98) |
| Median (range) testosterone level(IQR), ng/ml | 3.78 (2.86, 5.05) | 4.11(3.05,5.32) | 3.84(2.91,5.01) |
| Median (range) PSA level (IQR), ng/ml | 19.9 (8.2, 68) | 19.8 (9.4, 46) | 17.4 (8.4, 56) |
| Stage of prostate cancer: number( % ) | |||
| Localized | 59 (29) | 69 (33) | 63 (31) |
| Locally advanced | 62 (31) | 64 (31) | 52 (26) |
| Metastatic | 41 (20) | 37 (18) | 47 (23) |
| Not classifiable | 40 (20) | 37 (18) | 39 (19) |
| Gleason score: number( % ) | |||
| 2-4 | 21 (11) | 20 (10) | 24 (12) |
| 5-6 | 67 (34) | 68 (33) | 63 (32) |
| 7 | 56 (28) | 63 (30) | 62 (31) |
| 8-10 | 56 (28) | 56 (27) | 51 (26) |
| Anderson | Degarelix (n=27) | Goserelin (n=13) | |
| Mean age (range), year | 68 (53, 87) | 72 (57, 85) | |
| Median (range) testosterone level(IQR), ng/ml | 4.2 (1.1, 6.7) | 3.9 (2.7, 7.4) | |
| Median (range) PSA level (IQR), ng/ml | 54.8 (8, 1914) | 41.1 (14.6, 348) | |
| Stage of prostate cancer: number( % ) | |||
| Localized | 4 (15) | 0 (0) | |
| Locally advanced | 4 (15) | 1 (8) | |
| Metastatic | 10 (37) | 4 (31) | |
| Not classifiable | 9 (33) | 8 (62) | |
| Gleason score: number( % ) | |||
| 5-6 | 2 (7) | 0 (0) | |
| 7-10 | 25 (93) | 13 (100) | |
| Mean (standard error) of IPSS general score | 20.1 (1.1) | 21.1 (1.6) | |
| Mean (standard error) of IPSS QoL score | 3.6 (0.3) | 3.2 (0.5) | |
| Mean (standard error) of prostate volume, ml | 53.5 )5.5( | 50.3 (4.5) | |
| Mason | Degarelix (n=180) | Goserelin (n=64) | |
| Mean (standard deviation)age, year | 70.6 (6.37) | 70.8 (5.96) | |
| Mean (standard deviation) testosterone level, ng/ml | 4.18 (1.72) | 4.45 (1.49) | |
| Median (range) testosterone, ng/ml | 3.92 (0.58, 11.2) | 4.42 (0.19, 8.16) | |
| Mean (standard deviation) PSA, ng/ml | 17.4 (30.1) | 13.4 (12.9) | |
| Median (range) PSA, ng/ml | 10.0 (2.5, 339) | 9.75 (2.9, 80) | |
| Stage of prostate cancer: number( % ) | |||
| Localized | 111 (62) | 41 (64) | |
| Locally advanced | 63 (35) | 20 (31) | |
| Not classifiable | 6 (3) | 3 (5) | |
| Gleason score: number( % ) | |||
| 2-6 | 41 (23) | 12 (19) | |
| 7 | 97 (54) | 42 (66) | |
| 8-10 | 42 (23) | 10 (16) | |
| Mean (standard error) of IPSS general score | 9.5 (6.71) | 8.5 (6.3) | |
| Mean (standard error) of IPSS QoL score | 2.27 (1.63) | 1.94 (1.56) | |
| Mean (standard error) of prostate volume, ml | 50.9 (20.3) | 52.5 (18.8) | |
| Axcrona | Degarelix (n=82) | Goserelin (n=97) | |
| Mean (standard deviation) age, year | 71.9 (7.71) | 73 (7.1) | |
| Mean (standard deviation) testosterone level, ng/ml | 4.25 (1.88) | 4.43 (1.64) | |
| Median (range) testosterone, ng/ml | 4.08 (0.32, 10.8) | 4.33 (0.13, 9.61) | |
| Mean (standard deviation) PSA, ng/ml | 277 (937) | 148 (438) | |
| Median (range) PSA, ng/ml | 27.8 (1.9, 6206) | 15.6 (3, 2829) | |